CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 107 filers reported holding CLOVIS ONCOLOGY INC in Q2 2013. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $336,000 | -25.2% | 166,500 | +0.4% | 0.00% | – |
Q4 2021 | $449,000 | -72.5% | 165,800 | -54.7% | 0.00% | -100.0% |
Q3 2021 | $1,631,000 | +28.4% | 365,800 | +67.1% | 0.00% | 0.0% |
Q2 2021 | $1,270,000 | +114.5% | 218,900 | +159.7% | 0.00% | – |
Q1 2021 | $592,000 | +46.2% | 84,300 | 0.0% | 0.00% | – |
Q4 2020 | $405,000 | -26.2% | 84,300 | -10.4% | 0.00% | – |
Q3 2020 | $549,000 | -37.3% | 94,100 | -27.4% | 0.00% | -100.0% |
Q2 2020 | $875,000 | +67.9% | 129,700 | +58.4% | 0.00% | – |
Q1 2020 | $521,000 | -29.6% | 81,900 | +15.4% | 0.00% | – |
Q4 2019 | $740,000 | +126.3% | 71,000 | -14.6% | 0.00% | – |
Q3 2019 | $327,000 | -68.2% | 83,140 | +20.4% | 0.00% | -100.0% |
Q2 2019 | $1,027,000 | -78.5% | 69,040 | -64.1% | 0.00% | -66.7% |
Q1 2019 | $4,774,000 | -36.6% | 192,340 | -54.1% | 0.00% | -50.0% |
Q4 2018 | $7,526,000 | -81.9% | 419,040 | -70.4% | 0.01% | -77.8% |
Q3 2018 | $41,548,000 | -4.1% | 1,414,652 | +48.4% | 0.03% | -10.0% |
Q2 2018 | $43,334,000 | -30.3% | 953,023 | -19.1% | 0.03% | -33.3% |
Q1 2018 | $62,197,000 | -8.8% | 1,177,977 | +17.5% | 0.04% | -8.2% |
Q4 2017 | $68,197,000 | -13.9% | 1,002,897 | +4.3% | 0.05% | -16.9% |
Q3 2017 | $79,250,000 | -11.7% | 961,777 | +0.3% | 0.06% | -14.5% |
Q2 2017 | $89,765,000 | +87.0% | 958,721 | +27.1% | 0.07% | +81.6% |
Q1 2017 | $48,015,000 | +2247.9% | 754,122 | +1538.0% | 0.04% | +1800.0% |
Q4 2016 | $2,045,000 | +23.2% | 46,040 | 0.0% | 0.00% | +100.0% |
Q3 2016 | $1,660,000 | +161.0% | 46,040 | -0.6% | 0.00% | 0.0% |
Q2 2016 | $636,000 | -28.5% | 46,340 | 0.0% | 0.00% | 0.0% |
Q1 2016 | $890,000 | -45.1% | 46,340 | 0.0% | 0.00% | 0.0% |
Q4 2015 | $1,622,000 | -61.9% | 46,340 | 0.0% | 0.00% | -75.0% |
Q3 2015 | $4,261,000 | +5.0% | 46,340 | +0.3% | 0.00% | +33.3% |
Q2 2015 | $4,060,000 | +18.4% | 46,200 | 0.0% | 0.00% | 0.0% |
Q1 2015 | $3,429,000 | +31.1% | 46,200 | -1.1% | 0.00% | +50.0% |
Q4 2014 | $2,615,000 | +28.4% | 46,700 | +4.0% | 0.00% | 0.0% |
Q3 2014 | $2,037,000 | +11.3% | 44,900 | +1.6% | 0.00% | 0.0% |
Q2 2014 | $1,830,000 | -27.0% | 44,200 | +22.1% | 0.00% | 0.0% |
Q1 2014 | $2,508,000 | +21.3% | 36,200 | +5.5% | 0.00% | 0.0% |
Q4 2013 | $2,067,000 | -92.7% | 34,300 | -92.6% | 0.00% | -92.9% |
Q3 2013 | $28,244,000 | +21.0% | 464,698 | +33.4% | 0.03% | +12.0% |
Q2 2013 | $23,336,000 | – | 348,402 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 407,416 | $14,259,560,000 | 8.34% |
Palo Alto Investors LP | 3,547,719 | $124,170,000 | 6.91% |
Antipodean Advisors LLC | 1,268,658 | $44,403,000 | 6.48% |
Redmile Group, LLC | 1,795,936 | $62,858,000 | 4.70% |
HealthCor Management, L.P. | 1,525,000 | $53,375,000 | 3.24% |
PointState Capital LP | 3,503,900 | $122,637,000 | 3.12% |
NEA Management Company, LLC | 1,139,890 | $39,896,000 | 2.54% |
CLIFTON PARK CAPITAL MANAGEMENT, LLC | 612,500 | $21,438,000 | 2.44% |
PFM Health Sciences, LP | 2,078,440 | $72,745,000 | 2.21% |
Partner Investment Management, L.P. | 35,300 | $1,236,000 | 2.03% |